Skip to main content

Table 1 Patients background

From: The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy

  Control group (n = 142) Cooling group (n = 40) P-value
Age (min-max) 59.7 ± 11.5 (35–84) 56.5 ± 10.4 (32–77) 0.144
Cancer type Ovarian (n = 80)
Cervical (n = 14)
Endometrial (n = 48)
Ovarian (n = 23)
Cervical (n = 9)
Endometrial (n = 8)
0.053
Regimen TC ± BV (n = 137)
TP (n = 2)
TAC or TEC (n = 3)
TC ± BV (n = 35)
TP (n = 5)
0.004
Concomitant platinum CBDCA (n = 140)
CDDP (n = 2)
CBDCA (n = 35)
CDDP (n = 5)
0.006
Cycle 5.9 ± 0.4 5.9 ± 0.4 0.624
Body-surface area (m2) 1.526 ± 0.151 1.483 ± 0.127 0.233
Initial PTX dose (mg/m2) 170.2 ± 6.9 171.2 ± 8.4 0.944
Cumulative PTX dose (mg/m2) 997.4 ± 78.9 1010.1 ± 95.1 0.483
Cumulative Platinum dose (mg/m2) CBDCA; 2291.3 ± 391.7
CDDP; 324.8 ± 34.3
CBDCA; 2332.2 ± 301.6
CDDP; 295.7 ± 5.5
0.565
0.311
  1. The value of age, cycle, body-surface area, initial PTX dose, cumulative PTX dose, and cumulative platinum dose were indicated as means ± standard deviation and its p values were calculated by unpaired t-test. The p value of cancer type, regimen, concomitant platinum were calculated by chi-square test. PTX paclitaxel, CBDCA carboplatin, CDDP cisplatin, TC ± BV bevacizumab ± paclitaxel + carboplatin, TP paclitaxel + cisplatin, TAC paclitaxel + doxorubicin + carboplatin, TEC paclitaxel + epirubicin + carboplatin